| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30058051 | HIV | ENSG00000151577.14 | protein_coding | DRD3 | No | No | 1814 | A1A4V4 E9PCM4 P35462 X5D2G4 |
| TVIS20057150 | HPV | ENSG00000151577.14 | protein_coding | DRD3 | No | No | 1814 | A1A4V4 E9PCM4 P35462 X5D2G4 |
| TVIS20057354 | HPV | ENSG00000151577.14 | protein_coding | DRD3 | No | No | 1814 | A1A4V4 E9PCM4 P35462 X5D2G4 |
| TVIS20040604 | HPV | ENSG00000151577.14 | protein_coding | DRD3 | No | No | 1814 | A1A4V4 E9PCM4 P35462 X5D2G4 |
| TVIS44006680 | HTLV-1 | ENSG00000151577.14 | protein_coding | DRD3 | No | No | 1814 | A1A4V4 E9PCM4 P35462 X5D2G4 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | DRD3 |
|---|---|
| DrugBank ID | DB00413 |
| Drug Name | Pramipexole |
| Target ID | BE0000581 |
| UniProt ID | P35462 |
| Regulation Type | agonist |
| PubMed IDs | 18248314; 9617505; 22023785; 9638397 |
| Citations | Merlino G, Serafini A, Robiony F, Valente M, Gigli GL: Clinical experience with pramipexole in the treatment of restless legs syndrome. Expert Opin Drug Metab Toxicol. 2008 Feb;4(2):225-35. doi: 10.1517/17425255.4.2.225.@@Piercey MF: Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51.@@Chernoloz O, El Mansari M, Blier P: Long-term administration of the dopamine D3/2 receptor agonist pramipexole increases dopamine and serotonin neurotransmission in the male rat forebrain. J Psychiatry Neurosci. 2012 Feb;37(2):113-21. doi: 10.1503/jpn.110038.@@Dooley M, Markham A: Pramipexole. A review of its use in the management of early and advanced Parkinson's disease. Drugs Aging. 1998 Jun;12(6):495-514. doi: 10.2165/00002512-199812060-00007. |
| Groups | Approved; Investigational |
| Direct Classification | Aralkylamines |
| SMILES | CCCN[C@H]1CCC2=C(C1)SC(N)=N2 |
| Pathways | |
| PharmGKB | PA164742949 |
| ChEMBL | CHEMBL301265 |
